Oxygenta Pharmaceutical Reports Record Sales Amidst Declining Profitability in December 2024 Results
Oxygenta Pharmaceutical announced its financial results for the quarter ending December 2024, reporting net sales of Rs 33.21 crore, a notable year-on-year increase. However, the company faced challenges with a decline in profit before tax and operating profit, indicating difficulties in maintaining profitability.
Oxygenta Pharmaceutical has released its financial results for the quarter ending December 2024, showcasing a mix of trends within its performance metrics. The company reported net sales of Rs 33.21 crore, reflecting a significant year-on-year growth of 262.95%. This marks the highest quarterly sales figure recorded in the last five quarters, indicating a robust near-term sales trend.However, the financial results also highlight challenges for Oxygenta Pharma. The profit before tax less other income (PBT) stood at Rs -5.45 crore, representing a year-on-year decline of 54.39%. This figure is the lowest recorded in the past five quarters, suggesting a concerning trend in profitability. Additionally, the operating profit (PBDIT) was reported at Rs -4.35 crore, also the lowest in the same timeframe, further emphasizing the negative near-term operating profit trend. The profit after tax (PAT) was recorded at Rs -3.93 crore, showing a year-on-year decrease of 5.4%.
In light of these results, Oxygenta Pharmaceutical has experienced an adjustment in its evaluation.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
